These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 8174208)

  • 1. Decrease in penbutolol protein binding as a consequence of treatment with some alkylating agents.
    Aguirre C; Rodríguez-Sasiain JM; Calvo R
    Cancer Chemother Pharmacol; 1994; 34(1):86-8. PubMed ID: 8174208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unchanged protein binding of penbutolol in renal insufficiency: a possible role of carbamylation.
    Aguirre C; Calvo R; Rodriguez-Sasiain JM
    Int J Clin Pharmacol Ther Toxicol; 1993 Jan; 31(1):31-4. PubMed ID: 8444514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum protein binding of penbutolol in patients with hepatic cirrhosis.
    Aguirre C; Calvo R; Rodríguez Sasiaín JM
    Int J Clin Pharmacol Ther Toxicol; 1988 Nov; 26(11):566-9. PubMed ID: 3243661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma protein binding of penbutolol in pregnancy.
    Aquirre C; Rodriguez-Sasiain JM; Navajas P; Calvo R
    Eur J Drug Metab Pharmacokinet; 1988; 13(1):23-6. PubMed ID: 3396610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decrease in penbutolol central response as a cause of changes in its serum protein binding.
    Martínez Jordá R; Aguirre C; Calvo R; Rodríguez-Sasiaín JM; Erill S
    J Pharm Pharmacol; 1990 Mar; 42(3):164-6. PubMed ID: 1974610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinctive effects of mechlorethamine (NSC-762), cyclophosphamide (NSC-26271), and BCNU (NSC-409962) on transcription in Ehrlich cells.
    Rutman RJ; Avadhani NG
    Cancer Treat Rep; 1976 Apr; 60(4):471-6. PubMed ID: 1277223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein binding studies of furosemide and penbutolol.
    Gottschalk R; Sistovaris N
    Arzneimittelforschung; 1985; 35(6):899-902. PubMed ID: 4026914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alkylating agent resistance: in vitro studies with human cell lines.
    Frei E; Cucchi CA; Rosowsky A; Tantravahi R; Bernal S; Ervin TJ; Ruprecht RM; Haseltine WA
    Proc Natl Acad Sci U S A; 1985 Apr; 82(7):2158-62. PubMed ID: 3856890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitization of pancreatic tumor xenografts to carmustine and temozolomide by inactivation of their O6-Methylguanine-DNA methyltransferase with O6-benzylguanine or O6-benzyl-2'-deoxyguanosine.
    Kokkinakis DM; Ahmed MM; Chendil D; Moschel RC; Pegg AE
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3801-7. PubMed ID: 14506174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of the effects of alkylating agents 1,3-bis(2-chloroethyl)-1-nitrosourea, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea and nitrogen mustard on nuclear RNA synthesis and processing.
    Abelson HT; Karlan D; Penman S
    Biochim Biophys Acta; 1974 May; 349(3):389-401. PubMed ID: 4407850
    [No Abstract]   [Full Text] [Related]  

  • 11. Changes in sensitivity to cytotoxic agents occurring during the life history of monolayer cultures of a mouse tumour cell line.
    Twentyman PR; Bleehen NM
    Br J Cancer; 1975 Apr; 31(4):417-23. PubMed ID: 1156523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Penbutolol Pharmacokinetics: the influence of concomitant administration of cimetidine.
    Spahn H; Kirch W; Hajdu P; Mutschler E; Ohnhaus EE
    Eur J Clin Pharmacol; 1986; 29(5):555-60. PubMed ID: 3956561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of alkylating agents on the DNA replication of cultured Yoshida sarcoma cells.
    van der Steen J; van Wichen BH; Benckhuysen C
    Chem Biol Interact; 1982 Mar; 39(2):191-204. PubMed ID: 7060227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of penbutolol and its metabolites in renal insufficiency.
    Bernard N; Cuisinaud G; Pozet N; Zech PY; Sassard J
    Eur J Clin Pharmacol; 1985; 29(2):215-9. PubMed ID: 4076321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-resistance and glutathione-S-transferase-pi levels among four human melanoma cell lines selected for alkylating agent resistance.
    Wang YY; Teicher BA; Shea TC; Holden SA; Rosbe KW; al-Achi A; Henner WD
    Cancer Res; 1989 Nov; 49(22):6185-92. PubMed ID: 2804968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic cytotoxicity of the ribonucleotide reductase inhibitor didox (3,4-dihydroxy-benzohydroxamic acid) and the alkylating agent carmustine (BCNU) in 9L rat gliosarcoma cells and DAOY human medulloblastoma cells.
    Horvath Z; Höchtl T; Bauer W; Fritzer-Szekeres M; Elford HL; Szekeres T; Tihan T
    Cancer Chemother Pharmacol; 2004 Aug; 54(2):139-45. PubMed ID: 15133626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and pharmacodynamics of penbutolol in healthy and cancer subjects: role of altered protein binding.
    Aguirre C; Trocóniz IF; Valdivieso A; Jiménez RM; González JP; Calvo R; Rodríguez-Sasiaín JM
    Res Commun Mol Pathol Pharmacol; 1996 Apr; 92(1):53-72. PubMed ID: 8733828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Penbutolol: pharmacokinetics, effect on exercise tachycardia, and in vitro inhibition of radioligand binding.
    Brockmeier D; Hajdù P; Henke W; Mutschler E; Palm D; Rupp W; Spahn H; Verho MT; Wellstein A
    Eur J Clin Pharmacol; 1988; 35(6):613-23. PubMed ID: 2906875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence for reinitiation of proliferative activity following alkylation or radiation.
    Maruyama Y
    Int J Radiat Oncol Biol Phys; 1976; 1(9-10):903-9. PubMed ID: 977421
    [No Abstract]   [Full Text] [Related]  

  • 20. Ablation of murine jejunal crypts by alkylating agents.
    Moore JV
    Br J Cancer; 1979 Feb; 39(2):175-81. PubMed ID: 219878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.